Shares of AbbVie declined about 4.2% in pre-open trading after the company reported second-quarter 2026 results prior to the market open, eliminating some of the gains built up during a run toward record highs in the weeks before the release.
In an SEC filing dated July 6, AbbVie had already disclosed a $291 million charge related to acquired in-process research and development (IPR&D) and milestone payments for the second quarter. The company said this expense reduced both GAAP and adjusted diluted earnings per share by $0.17. That same filing narrowed the full-year adjusted diluted EPS guidance to a range of $13.91 to $14.11 while setting second-quarter adjusted EPS guidance at $3.57 to $3.61.
The Q2 guidance range was materially lower than the Street consensus estimate of about $3.77 per share, a gap that left the stock exposed to downside pressure when results were posted. Management had warned ahead of the report that one-time charges would negatively affect the upcoming earnings release, yet investor optimism carried the shares higher into the print, reducing the tolerance for disappointing near-term optics.
Analysts remained largely bullish into the report. Canaccord Genuity lifted its price target to $282 with a Buy rating, BMO Capital raised its target to $300 citing the strength of Skyrizi revenues, and RBC Capital moved its target up to $280 ahead of the earnings announcement. Those upward revisions contributed to elevated positioning among investors, which in turn increased the potential for a profit-taking reaction once guidance disappointed relative to consensus.
Options market activity had implied an expected move of roughly 4.2% in either direction around the earnings release. Today's pre-market decline tracks almost exactly with that implied volatility measure, suggesting the price action was consistent with market expectations priced in via options.
Market internals did not provide a broader explanation for the drop. The S&P 500 was higher by about 0.4%, the Dow Jones Industrial Average was up roughly 0.6%, and the Nasdaq Composite rose near 1.2% in the same session, indicating the selling pressure on AbbVie was company-specific rather than driven by weak macro conditions.
Investor appetite for biotech more broadly has been positive over the past month, with many names posting gains. In AbbVie's case, recent outperformance left some holders able to harvest gains after the earnings release. That dynamic - where a strong pre-earnings rally precedes a post-earnings pullback - appears to be at work here and may present buying opportunities for those seeking a lower entry point.
Notably, the stock remains well above its 52-week low of $189.79, and AbbVie's immunology franchise led by Skyrizi and Rinvoq continues to show growth. The pre-market decline therefore reads more like a short-term reaction to earnings optics and charge-related guidance than as evidence of a fundamental change to the company's longer-term prospects.
Bottom line: A disclosed $291 million IPR&D and milestone charge, combined with adjusted Q2 guidance below consensus, produced a selling reaction after a sizable pre-earnings rally. Analyst target increases sustained bullish sentiment heading into the report, but lofty positioning left limited room for error.